Consensus Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Delayed Australian S.E. 05:16:40 12/11/2026 +03			5-day change	1st Jan Change
13.50 ^AUD	-3.67%		-4.01%	+20.67%

11-10	Telix Pharmaceuticals Limited - Analyst/Investor Day
10-21	Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the Third Quarter Ended September 30, 2026	CI

Evolution of the Average Target: Telix Pharmaceuticals Limited

Evolution of the Target Price: Telix Pharmaceuticals Limited

Changes in Analyst Recommendations: Telix Pharmaceuticals Limited

db57493069e0e50918.sQ-8OxkY--EDurUv4V-zYXJRBKlN_MjJP0h-7Ru76s4.1TjvbltIo9Za4_dIli3pUl8ZN5sqxbygVS4Zi136uKHYTNVNcmCsklbp_A~ac1981f10f90f65a1f1854e3e7271d0c

Analysts' recommendations: Telix Pharmaceuticals Limited

10-21	Citi Adjusts Telix Pharmaceuticals's Price Target to AU$31	MT
10-20	Citi Adjusts Telix Pharmaceuticals' Price Target to AU$22	MT
09-15	Jarden Adjusts Telix Pharmaceuticals' Price Target to AU$21 from AU$20.70, Keeps at Buy	MT
09-15	Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says	MT
07-21	Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says	MT
07-17	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
07-03	Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%	MT
04-16	Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says	MT
04-13	Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says	MT
04-08	Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy	MT
04-08	Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies	MT
03-02	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
01-21	Telix Pharmaceuticals Poised for Growth With Strong Illuccix Sales, Gozellix Launch, Jefferies Says	MT
01-14	Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies	MT
12-12	Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says	MT
11-12	Alerts from law firm on Telix pharmaceuticals withdrawn	RE
11-12	Telix Reports Positive Results from TLX250-CDx Imaging Trial in Triple Negative Breast Cancer Patients, Shares Fall 3%	MT
07/10/25	Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target	MT
25/09/25	Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says	MT
23/09/25	UBS Adjusts Price Target on Telix Pharmaceuticals to $20 From $23, Maintains Buy Rating	MT
19/09/25	Telix Pharmaceuticals Shows Strong Growth Potential With Blockbuster Drug Prospect, Citi Says	MT
18/09/25	Citigroup Initiates Telix Pharmaceuticals at Buy With $22 Price Target	MT
21/08/25	Telix Pharmaceuticals' Profitability Expected to Rebound, Wedbush Says	MT
06/08/25	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy	MT
03/07/25	HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TELIX PHARMACEUTICALS LIMITED					+75.15%
	WUXI APPTEC CO., LTD.					+34.62%
	ARGENX SE					+16.21%
	LONZA GROUP AG					+8.35%
	BEONE MEDICINES AG					+9.01%
	IQVIA HOLDINGS INC.					+13.35%
	REVOLUTION MEDICINES, INC.					+42.36%
	CELLTRION, INC.					+35.65%
	GENMAB A/S					+13.29%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.4%
	Average					+26.94%
	Weighted average by Cap.					+21.79%